| Literature DB >> 31230373 |
Paolo Maria Matricardi1, Stephanie Dramburg1, Alberto Alvarez-Perea2,3, Darío Antolín-Amérigo4, Christian Apfelbacher5, Marina Atanaskovic-Markovic6, Uwe Berger7, Michael S Blaiss8, Simon Blank9, Elisa Boni10, Matteo Bonini11,12,13, Jean Bousquet14,15, Knut Brockow16, Jeroen Buters9, Victoria Cardona17,18, Jean-Christoph Caubet19, Özlem Cavkaytar20, Tania Elliott21, Ignacio Esteban-Gorgojo22, Joao A Fonseca23,24,25, James Gardner26,27, Philippe Gevaert28, Ileana Ghiordanescu29, Peter Hellings30,31, Karin Hoffmann-Sommergruber32, A Fusun Kalpaklioglu33, Farid Marmouz34, Ángela Meijide Calderón35, Ralph Mösges36,37, Alla Nakonechna38,39, Markus Ollert40,41, José Oteros9, Giovanni Pajno42, Catalina Panaitescu43, Daniel Perez-Formigo44,45, Oliver Pfaar46, Constantinos Pitsios47, Michael Rudenko48, Dermot Ryan49,50, Silvia Sánchez-García51,52, Jennifer Shih53, Salvatore Tripodi54, Lauri-Ann Van der Poel55, Harmieke van Os-Medendorp56, Gilda Varricchi57, Jörn Wittmann58, Margitta Worm59, Ioana Agache60.
Abstract
Mobile health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health-related services, data and information flow, patient self-management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the "Be He@lthy, Be Mobile" WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases. The results are summarized in this position paper, analyzing also the regulatory background with regard to the "General Data Protection Regulation" and Medical Directives of the European Community. The task force assessed the design, user engagement, content, potential of inducing behavioral change, credibility/accountability, and privacy policies of mHealth products. The perspectives of healthcare professionals and allergic patients are discussed, underlining the need of thorough investigation for an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the context of precision medicine, these could facilitate the change in perspective from clinician- to patient-centered care. The current and future potential of mHealth is then examined for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of mobile technologies and associated big data sets are outlined. Facts and recommendations for future mHealth initiatives within EAACI are listed.Entities:
Keywords: EAACI; allergy; digital health; mobile health technology; position paper
Mesh:
Year: 2019 PMID: 31230373 DOI: 10.1111/all.13953
Source DB: PubMed Journal: Allergy ISSN: 0105-4538 Impact factor: 13.146